Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib and 177Lu-PSMA-617 in mCRPC
NCT05113537Phase 2Recruiting
- Start
- Jul 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abemaciclib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms). Primary endpoints: Recommended Phase 2 Dose at 6 weeks, Dose Limiting Toxicities at 6 weeks and 1 more. Started Jul 2022; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05113537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113537.